Publications by authors named "Virginia Priest"
Article Synopsis
- Left atrial appendage closure (LAAC) using the Watchman device is found to be more cost-effective than warfarin and direct oral anticoagulants (DOACs) for stroke prevention in Japanese patients with non-valvular atrial fibrillation (NVAF).
- A lifetime analysis showed LAAC saves approximately JPY 1,878,335 (about $17,600) compared to warfarin and JPY 1,198,096 (around $11,226) compared to DOACs, while also providing more quality-adjusted life years (QALYs).
- The study indicates that LAAC is not only less expensive but also offers a better quality of life, making it a favorable
Purpose: The value of intravascular ultrasound (IVUS) guidance during peripheral vascular revascularization procedures is incompletely understood. Moreover, data on long-term clinical outcomes and costs are limited. The objective of this study was to compare outcomes and costs between IVUS and contrast angiography alone in patients undergoing peripheral revascularization procedures in Japan.
View Article and Find Full Text PDFAims: To examine the cost-effectiveness of intravascular ultrasound (IVUS) use during percutaneous coronary intervention (PCI) with drug-eluting stents (DES) in treating coronary artery disease (CAD).
Methods And Results: A Markov model was constructed with a lifetime horizon to compare costs and health outcomes between IVUS-guided PCI and PCI guided solely by angiography from an Italian healthcare payer perspective. The population examined included CAD patients undergoing PCI with DES.
Emergency department presentations with chest pain are expensive and often unrelated to coronary artery disease (CAD). Coronary computed tomographic angiography (CTA) may allow earlier discharge of low-risk patients, resulting in cost savings. We modeled clinical and economic outcomes of diagnostic strategies in patients with chest pain and at low risk of CAD: exercise electrocardiography (ECG), stress single-photon emission computed tomography (SPECT), stress echocardiography, and a CTA strategy comprising an initial CTA scan with confirmatory SPECT for indeterminate results.
View Article and Find Full Text PDFObjectives: To compare the cost effectiveness of azathioprine (AZA), methotrexate (MTX) and no immunosuppression for maintaining remission of moderate to severe inflammatory bowel disease (IBD) in New Zealand Caucasians, and to determine whether prospective testing for poor metabolisers of AZA by genotype or phenotype is cost effective.
Methods: Pharmacoeconomic models were developed to compare treatment costs and effects (QALYs) in theoretical populations of 1,000 IBD patients over a 1-year period. Efficacy and tolerability profiles for AZA and MTX were taken from the literature.